October 24, 2016 1:44 AM ET


Company Overview of OncoMed Pharmaceuticals, Inc.

Key Executives for OncoMed Pharmaceuticals, Inc.

NameBoard RelationshipsTitleAge
Paul J. Hastings 203 RelationshipsChairman, Chief Executive Officer and President56
Sunil Patel 13 RelationshipsChief Financial Officer and Senior Vice President of Corporate Development & Finance44
Jakob Dupont M.D.No RelationshipsChief Medical Officer and Senior Vice President51
Austin Gurney Ph.D.No RelationshipsCo-Chief Scientific Officer and Senior Vice President of Molecular & Cellular Biology52
Alicia J. Hager J.D., Ph.D.No RelationshipsVice President and General Counsel46
View More Key Executives

OncoMed Pharmaceuticals, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Paul J. Hastings 203 RelationshipsOncoMed Pharmaceuticals, Inc.56
Jack W. Lasersohn J.D. 31 RelationshipsThe Vertical Group63
Michael S. Wyzga MBA 74 RelationshipsAura Biosciences, Inc.61
Rick E. Winningham 94 RelationshipsTheravance Biopharma, Inc.56
Laurence A. Lasky Ph.D. 77 RelationshipsThe Column Group LLC65
View All Board Members

OncoMed Pharmaceuticals, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee MBAMichael S. Wyzga74 Relationships3 Executives
Compensation Committee Rick E. Winningham94 Relationships4 Executives
Nominating Committee J.D.Jack W. Lasersohn31 Relationships4 Executives
Corporate Governance Committee J.D.Jack W. Lasersohn31 Relationships4 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Not meaningful
Total Short Term Compensation$517.0K
Total Value of Options
Compensation as of Fiscal Year
OncoMed Pharmaceuticals, Inc. CEO Compensation
Industry Average


Nordic Nanovector ASA Announces Board Changes
October 22, 2016 7:48 PM ET
4SC AG Announces Executive Changes
October 21, 2016 9:18 AM ET
Rosetta Genomics Ltd. Appoints Mark R. Willig as Chief Commercial Officer
October 20, 2016 12:40 PM ET
ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors
October 20, 2016 12:30 PM ET
Proteon Therapeutics Inc. Appoints Paul J. Hastings as Chairman of Board of Directors
October 20, 2016 12:00 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OncoMed Pharmaceuticals, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.